A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.
2019
TPS2647Background: CAR T therapies have been successful against hematologic malignancies, but have benefited only a handful of patients with solid cancers. Glypican 3 (GPC3) is an attractive immuno...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI